Predict your next investment

Venture Capital
chengwei.com

See what CB Insights has to offer

Investments

133

Portfolio Exits

19

Funds

6

About Chengwei Capital

Chengwei Capital, founded in 1999 and based in Shanghai, China, is a venture capital firm targeting investments in the following sectors: communication software, enterprise software, financial services, IC design, niche component manufacturing, healthcare, and media sectors. Geographically, Chengwei Capital prefers investments in China.

Chengwei Capital Headquarter Location

Building C No. 33, Lane 672, Changle Road, Jing'an District

Shanghai, Shanghai, 200040,

China

021-54048566

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Chengwei Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Chengwei Capital in 1 CB Insights research brief, most recently on Nov 10, 2021.

Latest Chengwei Capital News

TandemAI Announces $25 Million Seed & Pre-series A Financing Led by OrbiMed and Chengwei Capital

Dec 22, 2021

Funding to advance the company’s proprietary, industry-leading, computational platform and support expansion of wet lab capacity December 22, 2021 07:08 AM Eastern Standard Time SUZHOU, China & SHANGHAI--( BUSINESS WIRE )--TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations. The company will tightly integrate the computational platform with wet labs for biophysics, medicinal chemistry, and biology in order to accelerate the design and optimization of drug candidates for partners. The round was led by OrbiMed and Chengwei Capital. “Advances in artificial intelligence tools rooted in rigorous biophysics represent a new frontier in drug discovery,” said David Wang, M.D., Ph.D., Senior Managing Director and Partner at OrbiMed, who will also join the company’s Board of Directors. “TandemAI has assembled an outstanding core team to leverage this opportunity with a vision for creating a new drug discovery engine that is based on accurate quantum mechanics, large scale experimental data, and artificial intelligence.” “The investments by OrbiMed and Chengwei Capital, both leading venture firms, are strong votes of confidence in our strategy, business model, and team,” said Jeff He, MBA, co-founder, and CEO of TandemAI. “The funds will accelerate our expansion and enable us to attract the best talent for our platform and discovery operations.” TandemAI’s co-founders bring deep experience and exceptional track records in building, leading, and financing innovative drug discovery and development organizations. Mr. He has more than 20 years of experience in senior business leadership roles at companies, including most recently at HiFiBiO, where he served as co-founder and COO, and Harbour BioMed, where he was a co-founder and CFO. Wei Tang, Ph.D., TandemAI’s COO, was previously the CEO of Shanghai ChemPartner and a member of its board of directors. Before joining ChemPartner, he served at Merck in several senior research roles, with his latest position as a Distinguished Senior Investigator. TandemAI is rapidly setting up state-of-the-art wet labs and high-performance computing clusters in China. About OrbiMed OrbiMed is a leading healthcare investment firm, with over $17 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. www.orbimed.com About Chengwei Capital Founded in 1999, Chengwei Capital is one of the world’s leading evergreen funds. Over the past 20 years, Chengwei has been involved in high-end manufacturing, Internet, semiconductor, corporate services, biotechnology, and other areas. Its cumulative total investment exceeds $2 billion U.S. dollars with more than 100 invested companies. Chengwei is based in Shanghai with offices globally. www.chengwei.com About TandemAI TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community. Learn more at www.tandemai.com Contacts

Chengwei Capital Investments

133 Investments

Chengwei Capital has made 133 investments. Their latest investment was in LightGene as part of their Series A - II on January 1, 2022.

CBI Logo

Chengwei Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/25/2022

Series A - II

LightGene

No

2

12/22/2021

Seed VC

TandemAI

$25M

Yes

8

12/21/2021

Seed VC

Full-Life Technologies

$10M

Yes

5

12/1/2021

Seed VC

Subscribe to see more

Subscribe to see more

10

11/29/2021

Series A

Subscribe to see more

Subscribe to see more

10

Date

1/25/2022

12/22/2021

12/21/2021

12/1/2021

11/29/2021

Round

Series A - II

Seed VC

Seed VC

Seed VC

Series A

Company

LightGene

TandemAI

Full-Life Technologies

Subscribe to see more

Subscribe to see more

Amount

$25M

$10M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

8

5

10

10

Chengwei Capital Portfolio Exits

19 Portfolio Exits

Chengwei Capital has 19 portfolio exits. Their latest portfolio exit was Silicon Therapeutics on February 26, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/26/2021

Acquired

$99M

6

7/9/2020

Acquired

3

11/8/2019

IPO

$99M

3

9/14/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/28/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/26/2021

7/9/2020

11/8/2019

9/14/2018

3/28/2018

Exit

Acquired

Acquired

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

3

3

10

10

Chengwei Capital Acquisitions

1 Acquisition

Chengwei Capital acquired 1 company. Their latest acquisition was AsiaInfo Linkage on January 15, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/15/2014

Growth Equity

$99M

Take Private

1

Date

1/15/2014

Investment Stage

Growth Equity

Companies

Valuation

$99M

Total Funding

Note

Take Private

Sources

1

Chengwei Capital Fund History

6 Fund Histories

Chengwei Capital has 6 funds, including Chengwei Preferred Holdings 2016.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/3/2016

Chengwei Preferred Holdings 2016

Multi-Stage Venture Capital

Closed

$452.77M

1

12/31/2004

Chengwei Evergreen Fund

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

Chengwei Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Chengwei Ventures Evergreen Advisors Fund

Subscribe to see more

Subscribe to see more

10

Fund9

Subscribe to see more

Subscribe to see more

10

Closing Date

2/3/2016

12/31/2004

12/31/2000

Fund

Chengwei Preferred Holdings 2016

Chengwei Evergreen Fund

Chengwei Fund I

Chengwei Ventures Evergreen Advisors Fund

Fund9

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$452.77M

$99M

$99M

Sources

1

10

10

10

10

Chengwei Capital Team

5 Team Members

Chengwei Capital has 5 team members, including current Managing Partner, Yangdong Shao.

Name

Work History

Title

Status

Shimo Li

Founder

Current

Yangdong Shao

Managing Partner

Current

Pei Kang

Managing Director

Current

Ping Ping

Managing Director

Current

Ye Sha

Managing Director

Current

Name

Shimo Li

Yangdong Shao

Pei Kang

Ping Ping

Ye Sha

Work History

Title

Founder

Managing Partner

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.